Early Life
Giammaria Giuliani, born February 20, 1978, embarked on his career in 2002 at Leo Burnett (Publicis Group). In 2004, he took on the role of Executive Vice President and Head of Research and Development at Giuliani SpA, a family pharmaceutical company founded in 1889 in Milan, Italy.
Rise to Success
Since 2014, Giuliani has been an active healthcare investor. His investment portfolio includes a 5% stake in Royalty Pharma, the world’s largest acquirer of pharmaceutical royalties. Royalty Pharma went public in 2020 and has generated revenue from blockbuster drugs. Giuliani and his brother also own stakes in HBM Healthcare Investments and other biotech companies. He is a Brown University trustee, and is part of the take private of Rothschild & Co.
Key Business Strategies
Giuliani's investment strategy focuses on the pharmaceutical sector, particularly on acquiring royalties and supporting biotech firms. He is involved in defining investment strategies for companies he serves on the board, making sure they align with their missions and values. He also develops and finances medical and scientific research projects, most notably through the Giuliani Foundation.
Philanthropy
Giuliani is dedicated to philanthropic efforts through the Giuliani Foundation, which supports education, health, and economic well-being in developing countries. The Giuliani Foundation also funds research into medical conditions. In August 2023, the Giuliani Foundation established the Giammaria and Sabrina Giuliani Endowed Faculty Support Fund at the Ragon Institute to support research in human health and the immune system.